VIE

Viela Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.00
-0.01
-0.03%
Closed 16:00 03/31 EDT
OPEN
37.80
PREV CLOSE
38.01
HIGH
39.88
LOW
36.15
VOLUME
82.53K
TURNOVER
--
52 WEEK HIGH
70.66
52 WEEK LOW
18.20
MARKET CAP
1.94B
P/E (TTM)
-16.1085
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VIE stock price target is 50.25 with a high estimate of 60.00 and a low estimate of 36.00.

EPS

VIE News

More
  • Viela Bio, Inc. (VIE) CEO Bing Yao on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 6d ago
  • VIELA BIO EPS misses by $5.15, beats on revenue
  • seekingalpha · 6d ago
  • Viela Bio, Inc. 2019 Q4 - Results - Earnings Call Presentation
  • Seeking Alpha - Article · 6d ago
  • Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
  • GlobeNewswire · 6d ago

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About VIE

Viela Bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for severe inflammation and autoimmune diseases. Its product pipeline includes Inebilizumab, VIB4920 and VIB7734. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. VIB4920 is a fusion protein designed to bind to CD40 ligand (CD40L) on activated T cells, blocking the interaction with CD40 expressed on B cells and preventing them from differentiating into plasma cells and memory B cells. VIB7734 is a treatment for autoimmune and related inflammatory diseases.
More

Webull offers kinds of Viela Bio Inc stock information, including NASDAQ:VIE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIE stock news, and many more online research tools to help you make informed decisions.